🎉 20 Years – 20 Voices 🎉 We are thrilled to present 20 voices that have been part of our incredible journey in the last 20 years. From internal champions to external collaborators and partners, each story reflects our vision to improve outcomes and quality of life for cancer patients. #20yearsITM #RadionuclideTherapy #Research Today, we are excited to share the words of Professor Dr. Wolfgang Weber and Bert van Eijk:
ITM Isotope Technologies Munich SE
Arzneimittelherstellung
Garching near Munich, Bavaria 15.398 Follower:innen
Dedicated to giving cancer patients better answers than "maybe".
Info
PASSION FOR PRECISION. ITM Isotope Technologies Munich SE is a privately owned biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes for use in cancer treatment. Since its foundation in 2004, ITM and its subsidiaries have established GMP manufacturing and a robust global supply network of a novel, first-in-class medical radioisotopes and generator platform for a new generation of targeted cancer diagnostics and therapies. Furthermore, ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development, which address a range of cancers such as neuroendocrine tumors, glioblastoma, osteosarcoma and bone metastases, as well as folate receptor α positive tumors like lung, ovarian or breast cancer. ITM’s main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve treatment outcomes and quality of life for cancer patients while at the same time reducing side effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology. For more information please visit: www.itm-radiopharma.com. Please see our Community Guidelines: https://isotope-technologies-munich.com/service/community-guidelines
- Website
-
http://www.itm-radiopharma.com
Externer Link zu ITM Isotope Technologies Munich SE
- Branche
- Arzneimittelherstellung
- Größe
- 501–1.000 Beschäftigte
- Hauptsitz
- Garching near Munich, Bavaria
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Gegründet
- 2004
- Spezialgebiete
- Theranostic radioisotope platform technologies, Global network to guarantee security of supply, Strategic alliances in order to further develop Theranostics und Driving force to establish global standards regarding safety and efficacy of radiopharmaceuticals
Orte
-
Primär
Lichtenbergstrasse 1
Garching near Munich, Bavaria 85748, DE
-
Am Gfild 1-11
Neufahrn bei Freising, 85375, DE
-
5 Vaughn Dr
Suite 390
Princeton, New Jersey 08540, US
Beschäftigte von ITM Isotope Technologies Munich SE
Updates
-
Welcome Andrew Cavey! 🎉 Every new beginning calls for a celebration, so we couldn’t resist welcoming our new CEO Dr. Andrew Cavey with a special gift on his first day at ITM Isotope Technologies Munich SE. In the spirit of September traditions, where here in Germany, a “Schultüte” filled with useful and tasty treats is given to pupils on their first day of school, Andrew received his ITM-Schultüte packed with practical gadgets to kickstart his journey. Andrew, we wish you a great start here at ITM! #Welcome #ITM #Radiopharmaceuticals
-
🎉 20 Years – 20 Voices 🎉 We are thrilled to present 20 voices that have been part of our incredible journey in the last 20 years. From internal champions to external collaborators and partners, each story reflects our vision to improve outcomes and quality of life for cancer patients. #20yearsITM #Quality #Teamwork Today, we are excited to share the words of Thabo Tselane GMD NTP Radioisotopes and Anji Knöppel:
-
🎉 20 Years – 20 Voices 🎉 We are thrilled to present 20 voices that have been part of our incredible journey in the last 20 years. From internal champions to external collaborators and partners, each story reflects our vision to improve outcomes and quality of life for cancer patients. #20yearsITM #radioisotopes #collaboration Today, we are excited to share the words of Josh Mailman and Liz Coxon:
-
🎉 20 Years – 20 Voices 🎉 We are thrilled to present 20 voices that have been part of our incredible journey in the last 20 years. From internal champions to external collaborators and partners, each story reflects our vision to improve outcomes and quality of life for cancer patients. #20yearsITM #innovation #radiopharmaceuticals Today, we are excited to share the words of Dr. Florian Herrmann and Assoc Professor Grace Kong:
-
We’re excited to share that our work in #RadiopharmaceuticalTherapy has been featured in a recent Handelsblatt article, highlighted in the Insight #Innovation category. Maike Telgheder provides valuable insights into how #radiopharmaceutical therapy is advancing treatment options for prostate cancer, a cause we're deeply committed to. We were pleased to host Ms. Telgheder at our NOVA facility in Neufahrn earlier this summer. We appreciate the opportunity to showcase our production processes and discuss our contributions to this growing industry. 📰 Read the full article in the latest print edition of Handelsblatt or on the online portal.
-
🎉 20 Years – 20 Voices 🎉 This year, ITM Isotope Technologies Munich SE proudly celebrates its 20th anniversary. For two decades we have been pioneers in the field of #radiopharmaceuticals, collaborating with key scientific, medical and industrial partners worldwide. #20yearsITM We are thrilled to present 20 voices that have been part of our incredible journey. From internal champions to external collaborators and partners, each story reflects our vision to improve outcomes and quality of life for cancer patients. Over the next few weeks, we will share excerpts from these stories. Today, we are excited to bring you the first of ten posts featuring Klaus Maleck and Roger Schibli:
-
Over the past two decades, #ITM has grown from a visionary startup to a global leader in the field of #radiopharmaceuticals. This achievement wouldn't have been possible without the dedication and hard work of our incredible team and the support of our partners. To commemorate this milestone, we have created a special microsite featuring insights from individuals who have been part of ITM’s evolution and growth. You'll find thoughtful reflections from our employees and valued partners. 🔗 Visit our 20th Anniversary Microsite: https://lnkd.in/dezKdp5Z 📽️ We’re also excited to share the story of ITM’s 20 year journey in a new video. Watch it now and celebrate with us 20 years of passion, precision and people! #ITM20Years 🎉
-
📸 #FridayRecap: It's always a pleasure to get together with colleagues, especially over ice cream and cake! Recently, we had not one, but two fantastic occasions to celebrate at ITM Isotope Technologies Munich SE: ✨Our big summer party: A wonderful day filled with a great barbecue, bingo, music, a special ITM cocktail and lots of fun activities. ✨Farewell party for @SteffenSchuster: An emotional and heartfelt event as we bid farewell to our esteemed CEO, Steffen Schuster, who will pass the baton to Andrew Cavey in September and join the ITM Supervisory Board. #ThankYouSteffen Such wonderful gatherings that showcased our strong ITM community spirit and #culture. Check out some of our behind-the-scenes photos:
-
Are you attending the 3rd Annual Targeted Radiopharmaceuticals Summit? 📅 Don’t miss ITM’s Dr. Danielle Meyrick’s presentation “Advancing the Future of Radiopharmaceutical Therapy”. In her symposium presentation she will review the clinical needs for alpha, beta and Auger emitting #isotopes for Radiopharmaceutical Therapy (#RPT) while exploring the past to guide future clinical trials and #radiopharmaceutical development. Looking forward to meeting you in San Diego, CA! #TRP2024 #Radiotherapy